Skip to content

Transcatheter aortic valve replacement for patients with aortic valve stenosis

Transcatheter aortic valve replacement for patients with aortic valve stenosis - Transcatheter aortic valve replacement

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009224
Enrollment
20
Registered
2012-11-01
Start date
2012-11-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe aortic valve stenosis

Interventions

Sponsors

Kurashiki Central Hospital Department of Cardiology Department of Cardiovascular Surgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients who have high risk for operative mortality or are 'non- operable' as determined by cardiologist and cardiovascular surgeon 2.Severe aortic valve stenosis with the mean pressure gradient more than 40 mmHg, velocity more than 4.0 m/sec, or aortic valve area less than 0.8 cm2 by ultrasound cardiography 3.Heart failure symptoms with the NYHA classification greater than class II 4.Patient or substitute decision-maker signed the written informed consent, which had been approved by the institutional review board or its equivalence

Exclusion criteria

Exclusion criteria: 1. Acute myocardial infarction within 1 month 2. Unicuspid, bicuspid aortic valve, or aortic valve stenosis without calcification 3. Severe aortic valve regurgitation 4. Cardiac intervention within 2 weeks 5. Prior valve surgery with artifical valve ring or severe mitral valve regurgitation with level 3 or 4 6. Leukopenia, acute anemia, thrombocytopenic purpura, or past history of coagulation disorder 7. Coronary artery disease with significant stenosis requiring intervention. 8. Unstable circulation requiring mechanical support 9. Emergency procedure 10. Obstructive or nonobstructive cardiomyopathy 11. Severe LV dysfunction (LVEF<20%) 12. Cardiac tumor, thrombus, vegetation in UCG 13. Active gastrointestinal ulcer or history of upper gastrointestinal bleeding within 3 months 14. Allergy to aspirin, heparin, ticropigin, or contrast medium 15. Aortic valve annulus smaller than 16 mm or larger than 25 mm 16. CVA or TIA within 1 month 17. Life expectancy less than 12 months due to non-cardiac disease 18. Involvement in another clinical trial 19. Active bacterial endocarditis or other active infections 20. Massive calcified cusp of aortic valve close to the coronary ostium 21. Allergy to cobalt-chromium alloy 22. Abdominal or thoracic aortic aneurysm or atheroma (diameters more than 5 cm ), and serious denaturation or anatomical features of thoracoabdominal aorta 23. Severe calcification, extreme tortuosity and vessel diameter less than 6.5 mm making the safe insertion of sheath introducer impossible from the common iliac artery through the femoral artery

Design outcomes

Primary

MeasureTime frame
Improvement of heart failure symptoms more than 1 grade in the NYHA classification at the 6th postoperative month

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026